These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9664949)

  • 1. Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection.
    Morris-Stiff G; Talbot D; Balaji V; Baboolal K; Callanan K; Hails J; Moore R; Manas D; Lord R; Jurewicz WA
    Transpl Int; 1998; 11 Suppl 1():S78-81. PubMed ID: 9664949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single centre experience with mycophenolate mofetil for refractory rejection in cadaveric renal transplantation.
    Morris-Stiff G; Jurewicz WA
    Transpl Int; 1998; 11(3):204-7. PubMed ID: 9638849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation.
    Eberhard OK; Kliem V; Oldhafer K; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
    Transplantation; 1996 May; 61(9):1345-9. PubMed ID: 8629294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity.
    Hariharan S; Munda R; Cavallo T; Demmy AM; Schroeder TJ; Alexander JW; First MR
    Transplantation; 1996 Apr; 61(8):1161-5. PubMed ID: 8610411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
    Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.
    Ferraresso M; Ghio L; Edefonti A; Garavaglia R; Berardinelli L
    Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.
    Murphy GJ; Waller JR; Sandford RS; Furness PN; Nicholson ML
    Br J Surg; 2003 Jun; 90(6):680-6. PubMed ID: 12808614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
    McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
    J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
    Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus as a rescue immunosuppressant after heart transplantation.
    De Bonis M; Reynolds L; Barros J; Madden BP
    Eur J Cardiothorac Surg; 2001 May; 19(5):690-5. PubMed ID: 11343954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
    Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.
    Jordan ML; Shapiro R; Vivas CA; Scantlebury VP; Rhandhawa P; Carrieri G; McCauley J; Demetris AJ; Tzakis A; Fung JJ
    Transplantation; 1994 Mar; 57(6):860-5. PubMed ID: 7512293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.
    Plischke M; Riegersperger M; Dunkler D; Heinze G; Kikić Ž; Winkelmayer WC; Sunder-Plassmann G
    PLoS One; 2015; 10(8):e0135674. PubMed ID: 26270340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.